Alkomex GBN Pharma Focuses on Nutraceuticals & Functional Foods in India

New Delhi:  Alkomex GBN Pharma Group looks to tap nutraceutical and functional food segments to drive its growth in the Indian market, according to a company official.

The global pharma company aims for a significant increase in revenue in India by tapping into the nutraceutical and functional food segments, Alkomex GBN Pharma Group Scientific Advisor Dr. Sanjay Agrawal said.

Alkomex is also looking to launch innovative products backed by regional research to expand business in the country.

The company, part of Alkomex GBN, caters to the Indian market with a range of products, including ophthalmic solutions, dermatological products, multivitamins and nutritional supplements, and probiotics.

It has formed partnerships with companies like Danone Group to deliver high-quality healthcare products in the country. It also leverages contract manufacturing to meet the growing demand for these products.

To boost its presence, the company appointed Agrawal, a leading expert in health management and nutraceuticals, as its Scientific Advisor in November last year.

Alkomex GBN in November 2024 announced a global growth and dual-division strategy, focusing on expanding its footprint in Asia and other international markets. Under the strategy, its pharmaceutical division would drive advancements in ophthalmic, dermatological, and healthcare solutions, and the industrial division would provide innovative packaging and industrial materials.

Related Posts

  • Pharma
  • May 17, 2025
  • 10 views
Singapore May Avoid US Pharma Tariffs: Deputy PM

Singapore: Singapore may be able to escape tariffs on pharmaceutical exports to the United States even if Washington goes ahead with plans to introduce the sectoral tariff, Deputy Prime Minister…

  • Pharma
  • May 17, 2025
  • 41 views
Fire disrupts production at GSK Pharma’s contract manufacturing site

GlaxoSmithKline Pharmaceuticals (GSK Pharma) on Friday informed the stock exchanges that a fire had occurred at one of its contract manufacturing facilities, causing a temporary disruption in production at the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Singapore May Avoid US Pharma Tariffs: Deputy PM

Singapore May Avoid US Pharma Tariffs: Deputy PM

Fire disrupts production at GSK Pharma’s contract manufacturing site

Fire disrupts production at GSK Pharma’s contract manufacturing site

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

DCA seizes syrup stocks over misleading fever cure claim

DCA seizes syrup stocks over misleading fever cure claim

Mankind Pharma Faces Rs 341.86 Cr Tax Demand

Mankind Pharma Faces Rs 341.86 Cr Tax Demand